JPS6485928A - Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection - Google Patents

Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection

Info

Publication number
JPS6485928A
JPS6485928A JP62207336A JP20733687A JPS6485928A JP S6485928 A JPS6485928 A JP S6485928A JP 62207336 A JP62207336 A JP 62207336A JP 20733687 A JP20733687 A JP 20733687A JP S6485928 A JPS6485928 A JP S6485928A
Authority
JP
Japan
Prior art keywords
hiv
lavbru
monoclonal antibody
region
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62207336A
Other languages
Japanese (ja)
Inventor
Kasuriin Shiyuraibuaa Marii
Kei Toomasu Erein
Eru Kosando Uesurii
Eichi Gosuteingu Rarii
Esu Deitsukinson Edona
Matsukuruua Jiyanera
Jiei Todaro Jiyooji
Shii Nouinsukii Robaato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Systems Corp
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of JPS6485928A publication Critical patent/JPS6485928A/en
Pending legal-status Critical Current

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04B—POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS
    • F04B25/00—Multi-stage pumps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mechanical Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE: To obtain a composition capable of preventing or substantially suppressing the infection or cellular transmission of infectious HIV by compounding a monoclonal antibody which is specifically reactive to a neutralization region of HIV. CONSTITUTION: This composition is composed of at least one kind of monoclonal antibody which is specifically reactive to one or more neutralization regions of HIV, especially to gp100 epitope existing in an LAVBRU amino acid sequence 308-328 or its homolog of an env-region of an LAVBRU isolate or to an epitope existing in an LAVBRU amino acid sequence 278-319 or 315-363 or their homologs of a gag-region of an LAVBRU isolate. Further, treating efficiency can be enhanced by compounding another peptide or antibody (especially blocking peptide capable of suppressing virus proliferation) capable of disturbing the bonding of the HIV to a receptor and further weakening the HIV infection activity.
JP62207336A 1986-08-20 1987-08-20 Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection Pending JPS6485928A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89827386A 1986-08-20 1986-08-20
US4502687A 1987-05-01 1987-05-01
US6799687A 1987-06-29 1987-06-29

Publications (1)

Publication Number Publication Date
JPS6485928A true JPS6485928A (en) 1989-03-30

Family

ID=27366600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62207336A Pending JPS6485928A (en) 1986-08-20 1987-08-20 Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection

Country Status (28)

Country Link
JP (1) JPS6485928A (en)
KR (1) KR920008744B1 (en)
AT (1) AT398080B (en)
AU (1) AU616156B2 (en)
BE (1) BE1000811A4 (en)
CH (1) CH675728A5 (en)
CS (1) CS275838B6 (en)
DE (1) DE3727703A1 (en)
DK (1) DK433087A (en)
ES (1) ES2010727A6 (en)
FI (1) FI873553A (en)
FR (1) FR2603107B1 (en)
GB (1) GB2196634B (en)
GR (1) GR871298B (en)
HU (1) HU214439B (en)
IE (1) IE60671B1 (en)
IL (1) IL83580A (en)
IT (1) IT1222518B (en)
LU (1) LU86972A1 (en)
NL (1) NL8701950A (en)
NO (2) NO300462B1 (en)
NZ (1) NZ221440A (en)
OA (1) OA08652A (en)
PL (1) PL155084B1 (en)
PT (1) PT85567B (en)
SE (1) SE506025C2 (en)
YU (1) YU152587A (en)
ZW (1) ZW15487A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503166A (en) * 1988-01-26 1991-07-18 アメリカ合衆国 Synthetic antigens that evoke anti-HIV responses
JPH03504556A (en) * 1987-05-29 1991-10-09 タノツクス・バイオシステムズ・インコーポレーテツド Monoclonal antibody that neutralizes HIV-1
JPH04243895A (en) * 1990-07-19 1992-08-31 Merck & Co Inc Cyclic hiv-based neutralizing determinant peptide
JPH04243896A (en) * 1990-07-19 1992-08-31 Merck & Co Inc Cyclic hiv-based neutralizing determinant peptide
JPH05310785A (en) * 1991-09-30 1993-11-22 Nitto Denko Corp Hiv-related cyclic peptide and adsorption material obtained by immobilizing the same
WO2010026940A1 (en) 2008-09-02 2010-03-11 日本特殊陶業株式会社 Spark plug

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP96A (en) * 1986-06-03 1990-08-12 The Usa Dept Of Commerce Small peptides which inhibit binding to T-4 receptors and act as immunogens.
AU625720B2 (en) * 1987-05-01 1992-07-16 Genetic Systems Corporation Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
FR2632310B1 (en) * 1988-06-06 1992-04-10 Pasteur Institut PEPTIDES HAVING PROTECTIVE PROPERTIES OF A PATHOGENIC VIRUS OF THE HIV TYPE IN SENSITIVE CELLS
JPH04502760A (en) * 1988-10-03 1992-05-21 レプリゲン・コーポレーション Novel HIV proteins and peptides effective in the diagnosis, prevention and treatment of AIDS
CA2025481A1 (en) * 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
SE9000333D0 (en) * 1990-01-31 1990-01-31 Britta Wahren MONOCLONAL ANTIBODY
SE468168B (en) * 1990-02-20 1992-11-16 Replico Medical Ab HIV-1, P24 PEPTIDES, DIAGNOSTIC ANTIGENS AND PROCEDURES FOR DIFFERENTIAL DIAGNOSTICS OF PRELIMINARY HIV-1 POSITIVE SERUM TESTS
JPH03271233A (en) * 1990-03-19 1991-12-03 Inst Pasteur Inducement of protective action against virus infection by synergism between peptides cor- responding to virus envelope glycoprotein and neutral epitope of its glycoprotein
DE69333537T2 (en) * 1992-03-27 2005-06-16 Advanced Immuni T, Inc. T-peptide and related peptides in the treatment of inflammation, including multiple sclerosis
CA2952475C (en) 2005-12-09 2022-08-09 Vectus Biosystems Limited Vip fragment for the treatment of myocardial fibrosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
DE122005000039I1 (en) * 1984-10-18 2006-02-23 Pasteur Institut DNA fragments of the GAG gene of LAV
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
DE3650011T2 (en) * 1985-04-08 1994-11-17 Genetic Systems Corp EXPRESSION AND DIAGNOSIS WITH GAG-CODED PEPTIDES THAT ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES AGAINST LAV.
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
DK171119B1 (en) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS virus envelope protein, expression vector carrying the envelope protein, transformants transformed with the expression vector, method of producing the virus envelope protein, method of detecting AIDS antibodies, method of determining AIDS virus, vaccine against AIDS, antibodies against the virus envelope protein and use of it to prepare a vaccine and for testing
ATE116006T1 (en) * 1985-04-29 1995-01-15 Genetic Systems Corp SYNTHETIC ANTIGENS FOR DETECTING AIDS.
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
JP2837669B2 (en) * 1985-11-07 1998-12-16 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ T-cell lymphotropic virus protein and its analysis
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
IE63109B1 (en) * 1986-06-23 1995-03-22 Genetic Systems Corp Human monoclonal antibody to lymphadenopathy-associated virus
EP0255190A3 (en) * 1986-08-01 1990-08-29 Repligen Corporation Recombinant polypeptides and their uses, inclusing assay for aids virus
JPH0762031B2 (en) * 1986-12-30 1995-07-05 アメリカ合衆国 Synthetic peptides that induce cell-mediated immunity to AIDS virus and AIDS virus proteins

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504556A (en) * 1987-05-29 1991-10-09 タノツクス・バイオシステムズ・インコーポレーテツド Monoclonal antibody that neutralizes HIV-1
JPH03503166A (en) * 1988-01-26 1991-07-18 アメリカ合衆国 Synthetic antigens that evoke anti-HIV responses
JPH04243895A (en) * 1990-07-19 1992-08-31 Merck & Co Inc Cyclic hiv-based neutralizing determinant peptide
JPH04243896A (en) * 1990-07-19 1992-08-31 Merck & Co Inc Cyclic hiv-based neutralizing determinant peptide
JPH05310785A (en) * 1991-09-30 1993-11-22 Nitto Denko Corp Hiv-related cyclic peptide and adsorption material obtained by immobilizing the same
WO2010026940A1 (en) 2008-09-02 2010-03-11 日本特殊陶業株式会社 Spark plug

Also Published As

Publication number Publication date
KR920008744B1 (en) 1992-10-09
NO934897D0 (en) 1993-12-29
FI873553A0 (en) 1987-08-17
CS8706136A2 (en) 1990-08-14
KR890002547A (en) 1989-04-10
OA08652A (en) 1988-11-30
NO302176B1 (en) 1998-02-02
FR2603107A1 (en) 1988-02-26
ATA208987A (en) 1994-01-15
GR871298B (en) 1988-01-12
NO873495L (en) 1988-02-22
IL83580A (en) 1992-11-15
BE1000811A4 (en) 1989-04-11
GB2196634A (en) 1988-05-05
LU86972A1 (en) 1988-03-02
IT8721678A0 (en) 1987-08-19
PT85567A (en) 1987-09-01
AT398080B (en) 1994-09-26
SE8703225L (en) 1988-02-21
NO300462B1 (en) 1997-06-02
FI873553A (en) 1988-02-21
DK433087D0 (en) 1987-08-19
IE872219L (en) 1988-02-20
NZ221440A (en) 1991-11-26
ZW15487A1 (en) 1988-09-14
NL8701950A (en) 1988-03-16
IE60671B1 (en) 1994-08-10
NO873495D0 (en) 1987-08-19
CH675728A5 (en) 1990-10-31
PL267401A1 (en) 1988-07-21
DE3727703A1 (en) 1988-05-05
CS275838B6 (en) 1992-03-18
AU616156B2 (en) 1991-10-24
IL83580A0 (en) 1988-01-31
PT85567B (en) 1991-02-08
ES2010727A6 (en) 1989-12-01
NO934897L (en) 1993-12-29
YU152587A (en) 1992-09-07
IT1222518B (en) 1990-09-05
HUT44619A (en) 1988-03-28
AU7720187A (en) 1988-05-19
SE8703225D0 (en) 1987-08-19
HU214439B (en) 1998-03-30
GB8719587D0 (en) 1987-09-23
SE506025C2 (en) 1997-11-03
PL155084B1 (en) 1991-10-31
FR2603107B1 (en) 1992-04-24
DK433087A (en) 1988-02-21
GB2196634B (en) 1991-05-15

Similar Documents

Publication Publication Date Title
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
HK1007686A1 (en) Anti-cd-4 antibodies blocking hiv-induced syncytia
CA2371714A1 (en) Streptococcus pneumoniae proteins and vaccines
ES2102347T3 (en) METHODS AND COMPOSITIONS FOR THE USE OF ENV POLYPEPTIDES AND ANTI-ENV ANTIBODIES OF HIV.
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
Hadden Immunotherapy of human immunodeficiency virus infection
ATE238420T1 (en) RECOMBINANT HUMANIZED ANTIBODY AGAINST HUMAN IMMUNO DEFICIENCY VIRUS
DE69227500T2 (en) Monoclonal antibodies useful in the therapy of HIV-1 infection
AU8010791A (en) Hiv monoclonal antibody
UA43350C2 (en) Peptide induced production antibodies having neutralizing activity concerning hiv-1 strains and/or isolates, and/or inhibite due to vil-1 injured cell fusion, farmaceutical agent for antibody formation, method for antibody obtaining, iga, antibody demonstrating counteractive activity neutralizing hiv-1 and/or inhibits due to vil-1 injured cell fusion
CA2412460A1 (en) Human monoclonal antibody against hepatitis c virus e2 glycoprotein
IL95457A (en) Preparations containing immunoconjugates for detection and treatment of infections
FI944561A0 (en) HIV-neutralizing recombinant human monoclonal antibodies for the prevention and treatment of HIV infection
ATE435034T1 (en) EXPRESSION AND CHARACTERIZATION OF AN HIV-1 ENVELOPE PROTEIN ASSOCIATED WITH A BROADLY REACTIVE NEUTRALIZING ANTIBODY RESPONSE.
ES2000615A6 (en) Monoclonal antibodies against tumour-associated glycoproteins, process for their preparation and their use.
AU7196098A (en) Induction of protection against viral infection
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1990006771A1 (en) Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
KR920700698A (en) Acanthus antiviral protein-monoclonal antibody conjugate
ES2278022T3 (en) ACTIVE NATURAL ANTIBODIES AGAINST HIV VIRUS.
WO1999045969A3 (en) Radioimmuno-pharmacon for treating the hiv-1 infection
MY106163A (en) Bcrf1 antagonists for treating epstein-barr virus infections.
ZA899533B (en) Medication for the treatment or prevention of hiv-virus infection through passive immunization and processes for its preparation
RU93004854A (en) PEPTIDES FOR VACCINATION AND INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
Buchacher Immortalisierung humaner peripherer B-Lymphozyten zur Produktion humaner monoklonaler Antikoerper (Humane monoklonale Antikoerper gegen HIV-1 zur passiven Immunisierung und Immuntherapie)